Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Other Non-Current Liabilities (2016 - 2025)

Catalyst Pharmaceuticals' Other Non-Current Liabilities history spans 13 years, with the latest figure at $209000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 33.65% year-over-year to $209000.0; the TTM value through Dec 2025 reached $209000.0, down 33.65%, while the annual FY2025 figure was $209000.0, 33.65% down from the prior year.
  • Other Non-Current Liabilities reached $209000.0 in Q4 2025 per CPRX's latest filing, up from $161000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $14.7 million in Q3 2022 to a low of $161000.0 in Q3 2025.
  • Average Other Non-Current Liabilities over 4 years is $5.0 million, with a median of $2.7 million recorded in 2024.
  • Peak YoY movement for Other Non-Current Liabilities: decreased 22.1% in 2024, then plummeted 94.22% in 2025.
  • A 4-year view of Other Non-Current Liabilities shows it stood at $14.1 million in 2022, then crashed by 78.8% to $3.0 million in 2023, then plummeted by 89.44% to $315000.0 in 2024, then tumbled by 33.65% to $209000.0 in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Other Non-Current Liabilities are $209000.0 (Q4 2025), $161000.0 (Q3 2025), and $309000.0 (Q2 2025).